Clinical outcomes in a large registry of patients with major depressive disorder treated with Transcranial Magnetic Stimulation.

Autor: Sackeim HA; Departments of Psychiatry and Radiology, Vagelos College of Physicians and Surgeons, Columbia University, New York, NY, USA. Electronic address: has1@columbia.edu., Aaronson ST; Sheppard Pratt Health System and the Department of Psychiatry, University of Maryland, Baltimore, MD, USA., Carpenter LL; Butler Hospital and Department of Psychiatry, Brown University, Providence, RI, USA., Hutton TM; Southern California TMS Center, Pasadena, CA, USA., Mina M; Neuronetics Inc., Malvern, PA, USA., Pages K; TMS of South Tampa, Tampa, FL, USA., Verdoliva S; NAMSA - St. Louis Park, Minneapolis, MN, USA., West WS; Nashville NeuroCare Therapy, Franklin, TN, USA.
Jazyk: angličtina
Zdroj: Journal of affective disorders [J Affect Disord] 2020 Dec 01; Vol. 277, pp. 65-74. Date of Electronic Publication: 2020 Aug 07.
DOI: 10.1016/j.jad.2020.08.005
Abstrakt: Background: Randomized clinical trials have demonstrated that Transcranial Magnetic Stimulation (TMS) is an effective treatment for episodes of major depressive disorder (MDD). However, characterization of outcomes in routine clinical practice is needed, as well as identification of patient- and treatment-related outcome predictors. This study documented patient-rated (PHQ-9) and clinician-rated (CGI-S) clinical outcomes in the NeuroStar® Advanced Therapy System Clinical Outcomes Registry.
Methods: Registry data were collected at 103 practice sites. Of 7759 participants, 5010 patients were included in an intent-to-treat (ITT) sample, defined as a primary MDD diagnosis, age ≥ 18, and completion of the PHQ-9 before TMS and with at least one PHQ-9 assessment after baseline. Completers (N = 3,814) were responders or had received ≥ 20 sessions and had an end of acute treatment PHQ-9 assessment. CGI-S ratings were obtained in smaller samples.
Results: In the total ITT and Completer samples, response (58-83%) and remission (28-62%) rates were notably high across self-report and clinician-administered assessments. Female patients and those treated with a larger number of pulses per session had superior clinical outcomes.
Limitations: Site participation in the registry was voluntary and treatment was open label.
Conclusions: The extent of clinical benefit reported by patients and clinicians following TMS in routine practice compares favorably with alternative interventions for treatment-resistant depression. Strong efficacy and the low side effect and medical risk profile suggest that TMS be evaluated as a first-line treatment for MDD. The findings derive from the largest registry of clinical outcomes in MDD for any treatment.
(Copyright © 2020. Published by Elsevier B.V.)
Databáze: MEDLINE
Externí odkaz: